Moving towards the transformation of value-based healthcare

Initially promoted by Novartis, we have managed to identify the needs and challenges in order to devise a tool that improves the conditions of access to high-cost medicines. In the first instance we focus on respiratory and dermatological diseases such as asthma, lung cancer, psoriasis, rheumatoid arthritis. And, in a second place, together with Sanofi we added multiple sclerosis and atopic dermatitis. In 9 months we developed and launched the first pilot despite going through the difficult context of the pandemic and we managed to speed up the system, reducing the time of access to treatment by more than 35%.

All the challenges faced and the experience of each of the people who used the tool provided us with information and encouraged us to go ahead. We have become a company that is committed to the new #VBHC value-based health paradigm, creating digital solutions that improve the quality and life experience of people with rare and chronic diseases.